Novel Oral GLP-1 Drug SAL0112 Matches Liraglutide Efficacy With Better Stability and Fewer Drug Interactions
SAL0112, a novel small-molecule biased GLP-1 receptor agonist, showed potent and selective Gαs pathway activation without desensitization, greater metabolic stability than danuglipron, and comparable efficacy to liraglutide in reducing body weight, blood glucose, and liver fat in diabetic mice.
Quick Facts
What This Study Found
SAL0112 demonstrated potent selective Gαs pathway GLP-1R activation without desensitization. Superior stability vs danuglipron in human/rat liver microsomes. Higher oral absorption in rats. Lower DDI potential on liver transporters vs danuglipron. Significant reductions in body weight, blood glucose (p<0.05), HbA1c (p<0.05), and insulin resistance (p<0.01) in diabetic mice. Resolved hepatic steatosis. Efficacy comparable to danuglipron and liraglutide.
Key Numbers
Tested across multiple assay platforms. Liver transporter interactions assessed. Stability tested across multiple species.
How They Did This
In vitro: HTRF, FLIPR, TR-FRET, and PathHunter assays for receptor pharmacology. Liver transporter tests in HEK293-OATP1B1/1B3 cells. Stability in multi-species liver microsomes. In vivo: PK in rats; efficacy in high-fat diet transgenic C57BL/6 mice expressing human GLP-1R.
Why This Research Matters
Most GLP-1 drugs are injectable peptides. The race to develop effective oral GLP-1 drugs is intense, with oral semaglutide being the only approved option. SAL0112 represents a new approach — biased agonism — that could offer better tolerability and fewer side effects while maintaining efficacy as an oral medication.
The Bigger Picture
The oral GLP-1 drug market is projected to be worth tens of billions. SAL0112 represents the 'biased agonism' approach — selectively activating beneficial pathways while avoiding those that cause nausea and other side effects. If this translates to humans, it could be a major advance in the GLP-1 space.
What This Study Doesn't Tell Us
Preclinical data only — no human studies. Transgenic mice expressing human GLP-1R don't fully predict human pharmacology. Direct comparison with oral semaglutide (the current market leader) was not performed. Long-term safety and tolerability unknown.
Questions This Raises
- ?Does biased Gαs agonism actually reduce GLP-1 side effects (nausea, vomiting) in humans?
- ?How does SAL0112 compare to oral semaglutide in head-to-head testing?
- ?Will the superior metabolic stability translate to better oral bioavailability in humans?
Trust & Context
- Key Stat:
- No receptor desensitization Unlike many GLP-1 agonists that lose effectiveness over time as receptors become desensitized, SAL0112 maintained full potency — a potential advantage for long-term treatment
- Evidence Grade:
- Rated preliminary: comprehensive preclinical characterization but no human data. The transgenic mouse model adds translational value but clinical trials are needed.
- Study Age:
- Published in 2024. Part of the active race to develop next-generation oral GLP-1 drugs.
- Original Title:
- Pharmacodynamic and pharmacokinetic profiles of a novel GLP-1 receptor biased agonist-SAL0112.
- Published In:
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 177, 116965 (2024)
- Authors:
- Sun, Jingchao, Xiao, Ying, Xing, Wei(2), Jiang, Wenjuan, Hu, Xuefeng, Li, Hongchao, Liu, Zhaojun, Jin, Qian, Ren, Peng, Zhang, Hongmei, Lobie, Peter E
- Database ID:
- RPEP-09345
Evidence Hierarchy
Frequently Asked Questions
What makes SAL0112 different from existing GLP-1 drugs?
Two things: it's a small molecule (pill form, not injection) and it's a 'biased agonist' — meaning it selectively activates the beneficial GLP-1 receptor pathway while potentially avoiding the one that causes nausea. Most current GLP-1 drugs activate all receptor pathways equally, contributing to side effects.
Could this replace injectable GLP-1 drugs like Ozempic?
Potentially, but it's very early. In mice, SAL0112 worked as well as the injectable drug liraglutide for weight loss, blood sugar control, and fatty liver resolution. It also showed advantages over another oral GLP-1 candidate (danuglipron) in stability and safety markers. Human clinical trials will determine if these benefits hold up.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09345APA
Sun, Jingchao; Xiao, Ying; Xing, Wei; Jiang, Wenjuan; Hu, Xuefeng; Li, Hongchao; Liu, Zhaojun; Jin, Qian; Ren, Peng; Zhang, Hongmei; Lobie, Peter E. (2024). Pharmacodynamic and pharmacokinetic profiles of a novel GLP-1 receptor biased agonist-SAL0112.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 177, 116965. https://doi.org/10.1016/j.biopha.2024.116965
MLA
Sun, Jingchao, et al. "Pharmacodynamic and pharmacokinetic profiles of a novel GLP-1 receptor biased agonist-SAL0112.." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024. https://doi.org/10.1016/j.biopha.2024.116965
RethinkPeptides
RethinkPeptides Research Database. "Pharmacodynamic and pharmacokinetic profiles of a novel GLP-..." RPEP-09345. Retrieved from https://rethinkpeptides.com/research/sun-2024-pharmacodynamic-and-pharmacokinetic-profiles
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.